Herpes zoster medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Herpes zoster}} {{CMG}}; L. Katie Morrison, MD; '''Associate Editor(s)-In-Chief:''' {{CZ}} ==Treatment== [[Image:Disease varicella3.jpg|thumb|right|Transmission electron mi...")
 
m (Changes made per Mahshid's request)
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
{{Herpes zoster}}
{{Herpes zoster}}
{{CMG}}; L. Katie Morrison, MD; '''Associate Editor(s)-In-Chief:''' {{CZ}}
{{CMG}}; L. Katie Morrison, MD; '''Associate Editor(s)-In-Chief:''' {{CZ}}, {{MD}}


==Treatment==
==Overview==
[[Image:Disease varicella3.jpg|thumb|right|Transmission electron micrograph of varicella-zoster virions]]
Several antiviral medicines—acyclovir, valacyclovir, and famciclovir—are available to treat shingles. These medicines will help shorten the length and severity of the illness. But to be effective, they must be started as soon as possible after the rash appears. Thus, people who have or think they might have shingles should call their healthcare provider as soon as possible to discuss treatment options. Analgesics (pain medicine) may help relieve the pain caused by shingles. Wet compresses, calamine lotion, and colloidal oatmeal baths may help relieve some of the itching.
[[Image:Chickenpox-virus.jpg|thumb|right|[[Electron microscope|Electron micrograph]] of [[Varicella zoster virus]]. Approx. 150.000-fold magnification.]]


Currently, there is no cure available for Herpes zoster, nor a treatment to effectively eliminate the virus from the body.  However, there are some treatments that can mitigate the length of the disease and alleviate certain side effects.
==Medical Therapy==
 
===Antimicrobial Regimen===
===Antiviral drugs===
::* 1. '''Varicella zoster treatment'''<ref name="pmid23863052">{{cite journal| author=Cohen JI| title=Clinical practice: Herpes zoster. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 3 | pages= 255-63 | pmid=23863052 | doi=10.1056/NEJMcp1302674 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23863052  }} </ref>
 
:::* 1.1 '''Non Immunocompromised person'''
[[Aciclovir|Acyclovir]] (an [[antiviral drug]]) inhibits replication of the viral DNA, and is used both as [[prophylaxis]] (''e.g.'', in patients with [[AIDS]]) and as therapy for herpes zoster. Other antivirals are [[valacyclovir]] and [[famciclovir]]. During the [[Acute (medical)|acute phase]], oral acyclovir should be given. Use of acylovir is most effective in moderating the progress of the symptoms, and in preventing post-herpetic neuralgia, if started within 24 to 72 hours of the onset of symptoms, so medical care should be obtained as soon as the condition is recognized.  [[Immunocompromised]] patients may respond best to intravenous acyclovir. In patients who are at high risk for recurrences, an oral dose of acyclovir, taken twice daily, is usually effective. It is also reported that the [[amino acid]] [[lysine]] inhibits the replication of herpes zoster.<ref>{{cite journal|last=Griffith|first=RS|coauthors=Walsh DE, Myrmel KH, Thmpson RW, and Behforooz A|title=Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis|journal=Dermatologica|date=1987|volume=175|issue=4|pages=183-190|id=PMID 3115841}}</ref>
::::* Preferred regimen (1): [[Acyclovir]] 500 mg PO five times a dayfor 7-10 days
 
::::* Preferred regimen (2): [[Famciclovir]] 500 mg PO tid  for 7 days
===Other drugs===
::::* Preferred regimen (3): [[Valacyclovir]] 1 g PO tid for 7 days
 
::::* Preferred regimen (4): Brivudin 125 mg PO qd for 7 days
[[Cimetidine]], a common component of over-the-counter heartburn medication, has been shown to lessen the severity of herpes zoster outbreaks in several different instances.<ref>{{cite journal|author=Kapinska-Mrowiecka M, &Toruwski G | title=Efficacy of cimetidine in treatment of herpes zoster in the first 5 days from the moment of disease manifestation. | journal= Pol Tyg Lek. | year=1996. | pages=338-339 | volume=51 | issue=23-26 | id=PMID 9273526}}</ref><ref>{{cite journal|author=Hayne ST, & Mercer JB|title=Herpes zoster: treatment with cemetidine|journal=Canadian Medical Association Journal|year=1983|pages=1284-1285| volume=129|issue=12|id=PMID 6652595}}</ref><ref>{{cite journal|author=Notmann J, Arieli J, Hart J, Levinsky H, Halbrecht I, & Sendovsky U | title=In vitro cell-mediated immune reactions in herpes zoster patients treated with cimetidine. | journal=Asian Pacific Journal Allergy and Immunology|year=1994|pages=51-58|volume=12|issue=1|id=PMID 7872992}}</ref>  This usage is considered an [[off-label use]] of the drug.  In addition, cimetidine and [[probenecid]] have been shown to reduce the renal clearance of aciclovir. <ref>{{cite journal|author=De Bony F, Tod M, Bidault R, On NT, Posner J, & Rolan P| title=Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir |journal=Antimicrobial Agents and Chemotherapy|year=2002|pages=458-463|volume=46 |issue=2|id=PMID 11796358}}</ref> The study showed these compounds reduce the rate, but not the extent, at which valaciclovir is converted into aciclovir. Renal clearance of aciclovir was reduced by approximately 24% and 33% respectively. In addition, respective increases in the peak plasma concentration of acyclovir of 8% and 22% were observed. The authors concluded that these effects were "not expected to have clinical consequences regarding the safety of valaciclovir".  Due to the tendency of aciclovir to precipitate in renal tubules, combining these drugs should only occur under the supervision of a physician.
:::* 1.2 '''Immunocompromised person requiring hospitalization or persons with sever neurologic complications'''
 
::::* Preferred regimen (1): [[Acyclovir]] 10 mg/ kg IV q8h for 7-10 days
===Complementary Therapies===
::::* Preferred regimen (2): [[Foscarnet]] 40 mg/ kg IV q8h until lesions are healed
Digestive Enzymes are available on prescription and in some over the counter preparations. Before the availability of antivirals, oral pancreatic enzyme therapy in shingles was used in some countries and later subjected to clinical and scientific research. A large scale multi-centre clinical study, using an oral preparation of such enzymes, has shown promising results.<ref name="pmid7713467">{{cite journal |author=Billigmann P |title=[Enzyme therapy--an alternative in treatment of herpes zoster. A controlled study of 192 patients] |language=German |journal=Fortschr. Med. |volume=113 |issue=4 |pages=43-8 |year=1995 |pmid=7713467 |doi=}}</ref> <ref name="pmid16813460">{{cite journal |author=Roxas M |title=Herpes zoster and postherpetic neuralgia: diagnosis and therapeutic considerations |journal=Alternative medicine review : a journal of clinical therapeutic |volume=11 |issue=2 |pages=102-13 |year=2006 |pmid=16813460 |doi=}}</ref> The results of another clinical study support the concept that oral enzyme therapy is beneficial in diseases characterized in part by TGF-beta overproduction that included shingles patients. <ref name="pmid11561866">{{cite journal |author=Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I |title=Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood |journal=Cancer Chemother. Pharmacol. |volume=47 Suppl |issue= |pages=S10-5 |year=2001 |pmid=11561866 |doi=}}</ref> TGF-β has also been found to be elevated in instances of VZV infection. <ref name="pmid15547808">{{cite journal |author=Kaygusuz I, Gödekmerdan A, Keleş E, ''et al'' |title=The role of viruses in idiopathic peripheral facial palsy and cellular immune response |journal=American journal of otolaryngology |volume=25 |issue=6 |pages=401-6 |year=2004 |pmid=15547808 |doi=}}</ref> <ref name="pmid11094200">{{cite journal |author=Sato M, Abe T, Tamai M |title=Expression of the Varicella Zoster Virus Thymidine Kinase and Cytokines in Patients with Acute Retinal Necrosis Syndrome |journal= |volume=44 |issue=6 |pages=693 |year=2000 |pmid=11094200 |doi=}}</ref>
::::* Note: Brivudin is not available in USA and has not been approved by FDA. [[Foscarnet]] is not approve by FDA
::* 2. '''Treatment of VZV complications'''<ref name="pmid17143845">{{cite journal| author=Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M et al.| title=Recommendations for the management of herpes zoster. | journal=Clin Infect Dis | year= 2007 | volume= 44 Suppl 1 | issue= | pages= S1-26 | pmid=17143845 | doi=10.1086/510206 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17143845  }} </ref>
:::* 2.1 '''VZV ophthalmicus'''
::::* Treatment includes the following
:::::* (1) [[Famciclovir]] {{or}} [[Valacyclovir]] for 7–10 days, preferably started within 72 h of rash onset (with [[Acyclovir]] IV given as needed for retinitis), to resolve acute disease and inhibit late inflammatory recurrences, {{and}} [[Prednisone]] 20 mg PO tid for 4 days or bid for 6 days, and then qd for 4 day
:::::* (2) Bacitracin-Polymyxin ophthalmic ointment administered bid ,to protect the ocular surface;
:::::* (3) Topical  [[Prednisolone]] 0.125%–1% 2–6 times daily prescribed and managed only by an ophthalmologist for corneal immune disease, episcleritis, scleritis, or iritis;
:::::* (4) [[Homatropine]] 5% bid as needed for iritis
:::::* (5) Latanaprost qd and/or Timolol maleate ophthalmic gel forming solution every morning)ocular pressure–lowering drugs given as needed for glaucoma
:::::* Note (1): Systemic steroids are indicated in the presence of moderate to severe pain or rash, particularly if there is significant edema, which may cause orbital apex syndrome through pressure on the nerves entering the orbit.  
:::::* Note (2): pain medications and cool to tepid wet compresses (if tolerated) and no topical antivirals, because they are ineffective
:::* 2.2 '''VZV retinitis'''
::::* Preferred regimen: [[Acyclovir]] IV  10–15 mg/kg q8h for 10–14 days followed by [[Valacyclovir]] PO 1 g tid  daily for 4–6 weeks
::* 3 '''Recommendations for treating varicella zoster virus (VZV) Infections in HIV-Infected adults and adolescents'''<ref>{{Cite web | title =VZV |https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/341/vzv }} </ref>
:::* 3.1 '''Herpes Zoster (Shingles)'''
::::* 3.1.1 '''Acute Localized Dermatomal'''
:::::* Preferred regimen (1): [[Valacyclovir]] 1000 mg PO tid for 7–10 days
:::::* Preferred regimen (2): [[Famciclovir]] 500 mg PO tid for 7–10 days
:::::* Alternative Therapy: [[Acyclovir]] 800 mg PO 5 times daily for 7–10 days
:::::* Note: Longer duration should be considered if lesions resolve slowly
::::* 3.1.2 '''Extensive Cutaneous Lesion or Visceral Involvement'''
:::::* Preferred regimen: [[Acyclovir]] 10–15 mg/kg IV q8h until clinical improvement is evident, then switch to ([[Valacyclovir]] 1 g PO tid, [[Famciclovir]] 500 mg PO tid, or [[Acyclovir]] 800 mg PO 5 times daily)—to complete a 10–14 day course, when formation of new lesions has ceased  and signs and symptoms of visceral VZV infection are improving
:::* 3.2 '''PORN (Progressive outer retinal necrosis)'''
::::* Preferred regimen: [[Ganciclovir]] 5 mg/kg and/or [[Foscarnet]] 90 mg/kg IV q12h {{and}} [[Ganciclovir]] 2 mg/0.05mL and/or foscarnet 1.2 mg/0.05mL intravitreal twice weekly.
::::* Note: Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with experienced ophthalmologist and optimize ART regimen.
::::* Note: [[Ganciclovir]] ocular implants are no longer commercially available
:::* 3.3 '''ARN (Acute retinal necrosis)'''
::::* Preferred regimen: [[Acyclovir]] 10-15 mg/kg IV q8h for 10–14 days, followed by [[Valacyclovir]] 1 g PO tid for 6 weeks {{and}} [[Ganciclovir]] 2 mg/0.05mL intravitreal qd/bid twice weekly
::::* Note: Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with experienced ophthalmologist


==References==
==References==
Line 24: Line 52:
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Herpesviruses]]
[[Category:Herpesviruses]]
[[Category:Infectious disease]]


{{WS}}
{{WS}}
{{WH}}
{{WH}}

Latest revision as of 17:59, 18 September 2017

Herpes zoster Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Herpes zoster from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Herpes Zoster
Congenital Varicella Syndrome

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Herpes zoster medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Herpes zoster medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Herpes zoster medical therapy

CDC on Herpes zoster medical therapy

Herpes zoster medical therapy in the news

Blogs on Herpes zoster medical therapy

Directions to Hospitals Treating Herpes zoster

Risk calculators and risk factors for Herpes zoster medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; L. Katie Morrison, MD; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Monalisa Dmello, M.B,B.S., M.D. [3]

Overview

Several antiviral medicines—acyclovir, valacyclovir, and famciclovir—are available to treat shingles. These medicines will help shorten the length and severity of the illness. But to be effective, they must be started as soon as possible after the rash appears. Thus, people who have or think they might have shingles should call their healthcare provider as soon as possible to discuss treatment options. Analgesics (pain medicine) may help relieve the pain caused by shingles. Wet compresses, calamine lotion, and colloidal oatmeal baths may help relieve some of the itching.

Medical Therapy

Antimicrobial Regimen

  • 1. Varicella zoster treatment[1]
  • 1.1 Non Immunocompromised person
  • Preferred regimen (1): Acyclovir 500 mg PO five times a dayfor 7-10 days
  • Preferred regimen (2): Famciclovir 500 mg PO tid for 7 days
  • Preferred regimen (3): Valacyclovir 1 g PO tid for 7 days
  • Preferred regimen (4): Brivudin 125 mg PO qd for 7 days
  • 1.2 Immunocompromised person requiring hospitalization or persons with sever neurologic complications
  • Preferred regimen (1): Acyclovir 10 mg/ kg IV q8h for 7-10 days
  • Preferred regimen (2): Foscarnet 40 mg/ kg IV q8h until lesions are healed
  • Note: Brivudin is not available in USA and has not been approved by FDA. Foscarnet is not approve by FDA
  • 2. Treatment of VZV complications[2]
  • 2.1 VZV ophthalmicus
  • Treatment includes the following
  • (1) Famciclovir OR Valacyclovir for 7–10 days, preferably started within 72 h of rash onset (with Acyclovir IV given as needed for retinitis), to resolve acute disease and inhibit late inflammatory recurrences, AND Prednisone 20 mg PO tid for 4 days or bid for 6 days, and then qd for 4 day
  • (2) Bacitracin-Polymyxin ophthalmic ointment administered bid ,to protect the ocular surface;
  • (3) Topical Prednisolone 0.125%–1% 2–6 times daily prescribed and managed only by an ophthalmologist for corneal immune disease, episcleritis, scleritis, or iritis;
  • (4) Homatropine 5% bid as needed for iritis
  • (5) Latanaprost qd and/or Timolol maleate ophthalmic gel forming solution every morning)ocular pressure–lowering drugs given as needed for glaucoma
  • Note (1): Systemic steroids are indicated in the presence of moderate to severe pain or rash, particularly if there is significant edema, which may cause orbital apex syndrome through pressure on the nerves entering the orbit.
  • Note (2): pain medications and cool to tepid wet compresses (if tolerated) and no topical antivirals, because they are ineffective
  • 2.2 VZV retinitis
  • Preferred regimen: Acyclovir IV 10–15 mg/kg q8h for 10–14 days followed by Valacyclovir PO 1 g tid daily for 4–6 weeks
  • 3 Recommendations for treating varicella zoster virus (VZV) Infections in HIV-Infected adults and adolescents[3]
  • 3.1 Herpes Zoster (Shingles)
  • 3.1.1 Acute Localized Dermatomal
  • Preferred regimen (1): Valacyclovir 1000 mg PO tid for 7–10 days
  • Preferred regimen (2): Famciclovir 500 mg PO tid for 7–10 days
  • Alternative Therapy: Acyclovir 800 mg PO 5 times daily for 7–10 days
  • Note: Longer duration should be considered if lesions resolve slowly
  • 3.1.2 Extensive Cutaneous Lesion or Visceral Involvement
  • Preferred regimen: Acyclovir 10–15 mg/kg IV q8h until clinical improvement is evident, then switch to (Valacyclovir 1 g PO tid, Famciclovir 500 mg PO tid, or Acyclovir 800 mg PO 5 times daily)—to complete a 10–14 day course, when formation of new lesions has ceased and signs and symptoms of visceral VZV infection are improving
  • 3.2 PORN (Progressive outer retinal necrosis)
  • Preferred regimen: Ganciclovir 5 mg/kg and/or Foscarnet 90 mg/kg IV q12h AND Ganciclovir 2 mg/0.05mL and/or foscarnet 1.2 mg/0.05mL intravitreal twice weekly.
  • Note: Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with experienced ophthalmologist and optimize ART regimen.
  • Note: Ganciclovir ocular implants are no longer commercially available
  • 3.3 ARN (Acute retinal necrosis)
  • Preferred regimen: Acyclovir 10-15 mg/kg IV q8h for 10–14 days, followed by Valacyclovir 1 g PO tid for 6 weeks AND Ganciclovir 2 mg/0.05mL intravitreal qd/bid twice weekly
  • Note: Duration of therapy is not well defined and should be determined based on clinical, virologic, and immunologic response in consultation with experienced ophthalmologist

References

  1. Cohen JI (2013). "Clinical practice: Herpes zoster". N Engl J Med. 369 (3): 255–63. doi:10.1056/NEJMcp1302674. PMID 23863052.
  2. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M; et al. (2007). "Recommendations for the management of herpes zoster". Clin Infect Dis. 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845.
  3. "VZV". Text "https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/341/vzv " ignored (help); Missing or empty |url= (help)

Template:WS Template:WH